Schwab US Dividend Equity ETF ( $SCHD ) has risen by 0.81% in the past week. It has experienced a 5-day net inflow of $42.05 million.
This is due, in part, to market sentiment on some of the ETF’s largest holdings. For example:
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- AbbVie has recently made headlines with its submission of a New Drug Application to the U.S. FDA for tavapadon, a potential treatment for Parkinson’s disease. The company also completed a Phase 1 study on ABBV-CLS-579, which could offer new treatment options for advanced solid tumors. Despite these developments, AbbVie has received mixed analyst ratings, with some maintaining a Hold position while others recommend a Buy. Financially, the company reported a quarterly revenue of $15.42 billion, though insider sentiment remains negative, with significant insider selling observed.
- Chevron is experiencing positive momentum as oil prices surge, driven by geopolitical tensions and unexpected declines in U.S. crude inventories. The rise in oil prices is benefiting Chevron’s stock, which is currently rated as a Moderate Buy by analysts. The stock has an average price target of $170.64, suggesting a potential upside. This favorable outlook is supported by strong refinery runs and increased demand for gasoline, positioning Chevron well in the current market environment.